Review



dma slides  (Thermo Fisher)


Bioz Verified Symbol Thermo Fisher is a verified supplier
Bioz Manufacturer Symbol Thermo Fisher manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Thermo Fisher dma slides
    Dma Slides, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dma slides/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    dma slides - by Bioz Stars, 2026-04
    90/100 stars

    Images



    Similar Products

    90
    SCIENION 672 dma slides
    672 Dma Slides, supplied by SCIENION, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/672 dma slides/product/SCIENION
    Average 90 stars, based on 1 article reviews
    672 dma slides - by Bioz Stars, 2026-04
    90/100 stars
      Buy from Supplier

    90
    Aquarray GmbH droplet microarray dma slides
    Droplet Microarray Dma Slides, supplied by Aquarray GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/droplet microarray dma slides/product/Aquarray GmbH
    Average 90 stars, based on 1 article reviews
    droplet microarray dma slides - by Bioz Stars, 2026-04
    90/100 stars
      Buy from Supplier

    90
    Aquarray GmbH droplet microarray (dma) slides
    Workflow for high‐throughput drug screening and hit validation. The droplet <t>microarray</t> chip uses minimal reagents (200 nL medium, 300 cells per spot) to screen 2208 FDA‐approved drugs rapidly and economically. The assay is validated using MTT assays in a standard 96‐well plate. On‐ and off‐target effects are assessed using Western blot and mass spectrometry. Drug target analysis is correlated with patient survival data from the Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases to facilitate personalized clinical treatment.
    Droplet Microarray (Dma) Slides, supplied by Aquarray GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/droplet microarray (dma) slides/product/Aquarray GmbH
    Average 90 stars, based on 1 article reviews
    droplet microarray (dma) slides - by Bioz Stars, 2026-04
    90/100 stars
      Buy from Supplier

    90
    Aquarray GmbH dma slides g-dd-202
    Workflow for high‐throughput drug screening and hit validation. The droplet <t>microarray</t> chip uses minimal reagents (200 nL medium, 300 cells per spot) to screen 2208 FDA‐approved drugs rapidly and economically. The assay is validated using MTT assays in a standard 96‐well plate. On‐ and off‐target effects are assessed using Western blot and mass spectrometry. Drug target analysis is correlated with patient survival data from the Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases to facilitate personalized clinical treatment.
    Dma Slides G Dd 202, supplied by Aquarray GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dma slides g-dd-202/product/Aquarray GmbH
    Average 90 stars, based on 1 article reviews
    dma slides g-dd-202 - by Bioz Stars, 2026-04
    90/100 stars
      Buy from Supplier

    90
    Aquarray GmbH dma slides cat. no. g-np-301
    Workflow for high‐throughput drug screening and hit validation. The droplet <t>microarray</t> chip uses minimal reagents (200 nL medium, 300 cells per spot) to screen 2208 FDA‐approved drugs rapidly and economically. The assay is validated using MTT assays in a standard 96‐well plate. On‐ and off‐target effects are assessed using Western blot and mass spectrometry. Drug target analysis is correlated with patient survival data from the Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases to facilitate personalized clinical treatment.
    Dma Slides Cat. No. G Np 301, supplied by Aquarray GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dma slides cat. no. g-np-301/product/Aquarray GmbH
    Average 90 stars, based on 1 article reviews
    dma slides cat. no. g-np-301 - by Bioz Stars, 2026-04
    90/100 stars
      Buy from Supplier

    90
    Thermo Fisher dma slides
    Workflow for high‐throughput drug screening and hit validation. The droplet <t>microarray</t> chip uses minimal reagents (200 nL medium, 300 cells per spot) to screen 2208 FDA‐approved drugs rapidly and economically. The assay is validated using MTT assays in a standard 96‐well plate. On‐ and off‐target effects are assessed using Western blot and mass spectrometry. Drug target analysis is correlated with patient survival data from the Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases to facilitate personalized clinical treatment.
    Dma Slides, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dma slides/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    dma slides - by Bioz Stars, 2026-04
    90/100 stars
      Buy from Supplier

    90
    Aquarray GmbH dma slides with side length square spots
    Validation of the screening protocol. A) Representative confocal laser scanning microscope (CLSM) images of hiPSCs cultivated in 200 nL droplets on <t>DMA</t> <t>slides</t> coated with Matrigel and stained for six pluripotency markers: SOX2, OCT‐4A, NANOG, TRA‐1‐60, SSEA4, and TRA‐1‐81. Three independent experiments ( n = 3) obtained comparable results. DAPI was used to counterstain nuclei. Scale bars: 50 µm. B) Bright‐field images of hiPSCs cultivated on positive (Matrigel, MG + ) and negative (no Matrigel, MG − ) controls. Scale bar: 100 µm. C) NANOG expression level was used as a read out for the primary screening. IF staining was carried out on DMA followed by automated microscopy. All colonies in one image were from the single droplet. Scale bar: 50 µm. D) Quantification of mean brightness (mean fluorescence intensity) of hiPSCs cultured on positive and negative controls and stained for the pluripotency marker NANOG. The mean fluorescence intensity was calculated as the total fluorescence intensity divided by the area (in pixels). *** p < 0.001, significant differences positive control and negative controls. ( Z ʹ value is between 0.5 and 1, corresponding to a high‐quality screening assay). Data were presented as mean ± 3SD. ( n = 3) E) Representative CLSM images of E‐cadherin expression in hiPSCs cultured on positive and negative control coatings. E‐cadherin mediates cell–cell interactions and contributes to stem cell colony formation and pluripotency. Thus, on the positive control coating, undifferentiated hiPSCs show high expression of E‐cadherin, while differentiated hiPSCs on the negative control coating show low‐to‐no E‐cadherin expression. DAPI was used to counterstain nuclei. Scale bar: 25 µm.
    Dma Slides With Side Length Square Spots, supplied by Aquarray GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dma slides with side length square spots/product/Aquarray GmbH
    Average 90 stars, based on 1 article reviews
    dma slides with side length square spots - by Bioz Stars, 2026-04
    90/100 stars
      Buy from Supplier

    Image Search Results


    Workflow for high‐throughput drug screening and hit validation. The droplet microarray chip uses minimal reagents (200 nL medium, 300 cells per spot) to screen 2208 FDA‐approved drugs rapidly and economically. The assay is validated using MTT assays in a standard 96‐well plate. On‐ and off‐target effects are assessed using Western blot and mass spectrometry. Drug target analysis is correlated with patient survival data from the Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases to facilitate personalized clinical treatment.

    Journal: Advanced Healthcare Materials

    Article Title: Repurposing FDA‐Approved Drugs for Temozolomide‐Resistant IDH1 Mutant Glioma Using High‐Throughput Miniaturized Screening on Droplet Microarray Chip

    doi: 10.1002/adhm.202300591

    Figure Lengend Snippet: Workflow for high‐throughput drug screening and hit validation. The droplet microarray chip uses minimal reagents (200 nL medium, 300 cells per spot) to screen 2208 FDA‐approved drugs rapidly and economically. The assay is validated using MTT assays in a standard 96‐well plate. On‐ and off‐target effects are assessed using Western blot and mass spectrometry. Drug target analysis is correlated with patient survival data from the Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases to facilitate personalized clinical treatment.

    Article Snippet: The droplet microarray (DMA) slides were purchased from Aquarray GmbH (catalog, IR0050241542, Eggenstein‐Leopoldshafen, Germany).

    Techniques: High Throughput Screening Assay, Drug discovery, Biomarker Discovery, Microarray, Western Blot, Mass Spectrometry

    Validation of the screening protocol. A) Representative confocal laser scanning microscope (CLSM) images of hiPSCs cultivated in 200 nL droplets on DMA slides coated with Matrigel and stained for six pluripotency markers: SOX2, OCT‐4A, NANOG, TRA‐1‐60, SSEA4, and TRA‐1‐81. Three independent experiments ( n = 3) obtained comparable results. DAPI was used to counterstain nuclei. Scale bars: 50 µm. B) Bright‐field images of hiPSCs cultivated on positive (Matrigel, MG + ) and negative (no Matrigel, MG − ) controls. Scale bar: 100 µm. C) NANOG expression level was used as a read out for the primary screening. IF staining was carried out on DMA followed by automated microscopy. All colonies in one image were from the single droplet. Scale bar: 50 µm. D) Quantification of mean brightness (mean fluorescence intensity) of hiPSCs cultured on positive and negative controls and stained for the pluripotency marker NANOG. The mean fluorescence intensity was calculated as the total fluorescence intensity divided by the area (in pixels). *** p < 0.001, significant differences positive control and negative controls. ( Z ʹ value is between 0.5 and 1, corresponding to a high‐quality screening assay). Data were presented as mean ± 3SD. ( n = 3) E) Representative CLSM images of E‐cadherin expression in hiPSCs cultured on positive and negative control coatings. E‐cadherin mediates cell–cell interactions and contributes to stem cell colony formation and pluripotency. Thus, on the positive control coating, undifferentiated hiPSCs show high expression of E‐cadherin, while differentiated hiPSCs on the negative control coating show low‐to‐no E‐cadherin expression. DAPI was used to counterstain nuclei. Scale bar: 25 µm.

    Journal: Advanced Healthcare Materials

    Article Title: Droplet Microarray Based Screening Identifies Proteins for Maintaining Pluripotency of hiPSCs

    doi: 10.1002/adhm.202200718

    Figure Lengend Snippet: Validation of the screening protocol. A) Representative confocal laser scanning microscope (CLSM) images of hiPSCs cultivated in 200 nL droplets on DMA slides coated with Matrigel and stained for six pluripotency markers: SOX2, OCT‐4A, NANOG, TRA‐1‐60, SSEA4, and TRA‐1‐81. Three independent experiments ( n = 3) obtained comparable results. DAPI was used to counterstain nuclei. Scale bars: 50 µm. B) Bright‐field images of hiPSCs cultivated on positive (Matrigel, MG + ) and negative (no Matrigel, MG − ) controls. Scale bar: 100 µm. C) NANOG expression level was used as a read out for the primary screening. IF staining was carried out on DMA followed by automated microscopy. All colonies in one image were from the single droplet. Scale bar: 50 µm. D) Quantification of mean brightness (mean fluorescence intensity) of hiPSCs cultured on positive and negative controls and stained for the pluripotency marker NANOG. The mean fluorescence intensity was calculated as the total fluorescence intensity divided by the area (in pixels). *** p < 0.001, significant differences positive control and negative controls. ( Z ʹ value is between 0.5 and 1, corresponding to a high‐quality screening assay). Data were presented as mean ± 3SD. ( n = 3) E) Representative CLSM images of E‐cadherin expression in hiPSCs cultured on positive and negative control coatings. E‐cadherin mediates cell–cell interactions and contributes to stem cell colony formation and pluripotency. Thus, on the positive control coating, undifferentiated hiPSCs show high expression of E‐cadherin, while differentiated hiPSCs on the negative control coating show low‐to‐no E‐cadherin expression. DAPI was used to counterstain nuclei. Scale bar: 25 µm.

    Article Snippet: DMA slides with 1 mm side length square spots (catalogue number: G‐np‐102) were purchased from Aquarray GmbH (Eggenstein‐Leopoldshafen, Germany).

    Techniques: Biomarker Discovery, Laser-Scanning Microscopy, Staining, Expressing, Microscopy, Fluorescence, Cell Culture, Marker, Positive Control, Screening Assay, Negative Control